Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy

Clin Infect Dis. 2020 Jun 24;71(1):207-210. doi: 10.1093/cid/ciz991.

Abstract

The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5-37) and GBP 1234 (569-2594) per patient.

Keywords: IV antibiotics; OPAT; OVIVA.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Ambulatory Care
  • Anti-Bacterial Agents / therapeutic use
  • Anti-Infective Agents* / therapeutic use
  • Arthritis, Infectious* / drug therapy
  • Humans
  • Infusions, Parenteral
  • Outpatients

Substances

  • Anti-Bacterial Agents
  • Anti-Infective Agents